Vanderbilt Center for Antibody Therapeutics (VCAT)

Crowe’s pediatric immune response research lauded

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

Digestive Disease Research Center lands major grant

The Vanderbilt Digestive Disease Research Center (VDDRC) celebrates its 15th anniversary this year with a third consecutive five-year renewal of its federal research grant.

Early study finds antibody that ‘neutralizes’ Zika virus

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

Preparing for a return of pox

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.

knight with sword and shield

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.

1 7 8 9 10 11 14